Introduction
============

Hepatitis C virus (HCV) infection has been detected in \~170 million patients worldwide, and chronic hepatitis C (CHC) infection is a major risk factor for cirrhosis and hepatocellular carcinoma, which are associated with high morbidity and mortality ([@b1-etm-0-0-7995],[@b2-etm-0-0-7995]). The traditional standard of care, interferon (IFN)-based therapies, may achieve sustained virological response (SVR) rates of \~50%, and have serious side effects ([@b3-etm-0-0-7995]). Direct-acting anti-virals (DAAs) are replacing IFN-based therapy as the standard of care, with SVR rates of \>90% ([@b4-etm-0-0-7995]). However, the recurrence rate in DAA-treated patients remains significant ([@b5-etm-0-0-7995],[@b6-etm-0-0-7995]).

Approximately two-thirds of HCV patients experience extra-hepatic manifestations in the cardiovascular, renal and central nervous systems, including mixed essential cryoglobulinemia, non-Hodgkin\'s lymphoma and glomerulonephritis ([@b7-etm-0-0-7995]--[@b9-etm-0-0-7995]). Almost 415 million individuals worldwide have diabetes mellitus. According to statistics, one patient succumbs to its complications every six seconds ([@b10-etm-0-0-7995]). CHC patients also have a higher prevalence of insulin resistance (IR) and type 2 diabetes mellitus (T2DM), and IR improvement can increase the positive response to antiviral therapy regardless of HCV genotype ([@b11-etm-0-0-7995]--[@b14-etm-0-0-7995]). CHC patients with IR have higher rates of liver fibrosis ([@b15-etm-0-0-7995]) and 20% lower rates of SVR compared to patients without IR ([@b16-etm-0-0-7995]). Of note, patients with T2DM have an elevated risk of acquiring HCV infection ([@b17-etm-0-0-7995]). This may be due to lower immunity in patients with T2DM. Therefore, for patients with T2DM patients, avoiding the need to share needles can reduce the risk of HCV infection.

IR in HCV patients has been reported to be mediated by the HCV core protein, which interferes with glucose metabolism and insulin signaling by inhibiting the expression of insulin receptor substrate (IRS)1 and IRS2 ([@b13-etm-0-0-7995],[@b18-etm-0-0-7995]--[@b20-etm-0-0-7995]). HCV-induced IR in the tissue of HCV-infected patients and animal models has also been indicated to be mediated via a number of cytokines, including tumor necrosis factor-α ([@b21-etm-0-0-7995]).

Viral clearance in HCV patients treated with pegylated interferon α-2a and ribavirin has been associated with reduced IR \[measured as a reduction in homeostasis model assessment (HOMA) scores after 24 weeks of therapy\] and reduced fasting serum insulin and serum glucose levels ([@b20-etm-0-0-7995],[@b22-etm-0-0-7995],[@b23-etm-0-0-7995]). By contrast, elevated HOMA-IR scores were indicated to be associated with a 3-fold increase in the risk of failure to achieve SVR in HCV patients treated with pegylated interferon plus ribavirin ([@b24-etm-0-0-7995]). SVR was associated with a reduction in HOMA-IR in patients with HCV genotype 1 infection, but not in patients infected with genotypes 2 or 3 ([@b25-etm-0-0-7995]), suggesting that viral factors have an important role in modulating the insulin signaling pathway. However, non-diabetic, non-cirrhotic patients with HCV genotype 1 infection treated with pegylated (Peg-)IFN plus ribavirin exhibited a reduction in IR, independent of the virological outcome ([@b26-etm-0-0-7995]). A recent meta-analysis reported that achieving SVR was associated with reduced IR at the follow-up visit, and also protected against the incidence of diabetes ([@b27-etm-0-0-7995]). However, this study was limited by the lack of randomized data comparing SVR to non-SVR patients.

Despite the discrepancies arising from differences in study design and variables evaluated, these results, along with the result that SVR was associated with a significant reduction in mean fasting glucose levels and fasting serum insulin levels ([@b22-etm-0-0-7995],[@b28-etm-0-0-7995]), suggest that SVR is linked to improved glycemic control in HCV patients. The present meta-analysis aimed to evaluate the effect of HCV treatment response on IR by comparing the reduction in IR among HCV patients who achieved SVR and those who did not (non-SVR group) after receiving IFN-based therapy.

Materials and methods
=====================

### Literature search strategy

The PRISMA guidelines were followed for the processes and reporting in the present systematic review and meta-analysis ([@b29-etm-0-0-7995]). To identify relevant studies for inclusion in the present meta-analysis, the PubMed, Cochrane and Embase databases were searched using combinations of the following search terms: 'HCV', 'hepatitis C', 'interferon', 'antiviral', 'treatment response' and 'insulin resistance'. The search strategy for PubMed included the terms 'insulin resistance' AND ('hepatitis C' OR 'HCV') AND ('antiviral' OR 'interferon'); the search filters were as follows: Abstract available; English language. The search included studies published in the time window from inception until December 19, 2017.

### Selection of studies

The inclusion criteria for the meta-analysis were as follows: i) Prospective and retrospective studies; ii) studies on HCV patients who received IFN-based therapy; iii) studies in which IR was evaluated in SVR patients and non-SVR patients; and iv) studies reporting quantitative outcomes. Exclusion criteria were as follows: i) Publication type: Reviews, letters, commentaries, editorials, case reports, personal communications; ii) studies in which patients received other interventions; and iii) studies which did not report quantitative primary outcomes.

A 2-step screening process was used to identify studies that would be included in the meta-analysis. The first step involved an evaluation of the title and abstract of each article, and citations not meeting the inclusion criteria and meeting the exclusion criteria were discarded. The second step involved the evaluation of full-text copies of the remaining citations to identify those that met all of the inclusion criteria and none of the exclusion criteria. The screening process and identification of eligible studies were performed by two independent reviewers JHH and NJL. A third reviewer, MLC, was consulted if there were any uncertainties regarding eligibility. The reference lists of the relevant studies were hand-searched to identify further studies that met the inclusion criteria.

### Data extraction and analysis

Data were extracted from the eligible studies by two independent reviewers. Regarding the presentation of patient characteristics in the studies selected, parameters including age were expressed as the mean ± standard deviation (SD) and information regarding gender as the percentage of males in the given groups. For the clinical outcomes, the incidence of IR and scores/levels of HOMA-IR, HOMA-β, fasting glucose and fasting insulin were summarized in terms of basal values and values at the end of treatment (EOT) for each of group, if available. Data were summarized as the percentage of affected patients regarding the incidence of IR and as the mean ± standard deviation for other categorical data. The effect size was set as the reduction of the incidence rate of IR, HOMA-IR scores and HOMA-β scores from the basal value to the value after EOT for the SVR and non-SVR groups from each study. For studies reporting on non-responders and relapsers, these data were combined into the non-SVR group. The reduction in the incidence rate of IR was defined as the difference in the reduction in the incidence rate of IR with a 95% confidence interval (95%CI; lower limit, upper limit) and P-value for comparison between the SVR and non-SVR groups; the reduction of HOMA-IR and HOMA-β scores was defined as the difference in reduction of the mean HOMA-IR and HOMA-β scores from the basal value to the value after EOT with 95%CI and P-value for comparison between the SVR and non-SVR groups; a combined effect was calculated for those studies with completed measurements.

For the effect size of reduction in the incidence rate of IR, a difference in the reduction of the IR incidence rate \>0 indicated that the SVR group had a greater reduction in the IR incidence rate than the non-SVR group; reduction in the IR incidence rate \<0 indicated that the SVR group had a smaller reduction in the IR incidence rate than the non-SVR group; reduction of IR incidence rate=0 indicated that the SVR and non-SVR groups had similar reduction rates. For the effect size of reduction in HOMA-IR and HOMA-β scores, an effect size of outcomes \<0 indicated that the SVR group had a greater reduction than the non-SVR group; an effect size of outcomes \>0 indicated that the non-SVR group had a greater reduction than the SVR group; and an effect size of outcomes=0 indicated that the SVR and non-SVR groups had a similar reduction in outcomes.

Study heterogeneity was evaluated using χ^2^-based Cochran\'s Q and I^2^ statistics. A random-effects model (DerSimonian-Laird method) was considered for the meta-analysis if Q statistics with P\<0.10 or I^2^\>50% were obtained; otherwise, a fixed-effects model (Mantel-Haenszel method) was employed for the meta-analysis. Regarding the Q statistics, P\<0.10 was considered to indicate statistical significance regarding heterogeneity. For the I^2^ statistics, heterogeneity was assessed as follows: I^2^=0--25% indicated no heterogeneity, I^2^=25--50% moderate heterogeneity, I^2^=50--75% high heterogeneity and I^2^=75--100% very high heterogeneity. A two-sided P\<0.05 was considered to indicate statistical significance. Sensitivity analysis was performed using a leave-one-out approach. According to Sterne *et al* ([@b30-etm-0-0-7995]) study, when the number of studies in the meta-analysis is \<10, funnel plot asymmetry should not be used. Therefore, in the current study, publication bias was not assessed due to the limitation in the number of studies. All statistical analyses were performed using the statistical software Comprehensive Meta-Analysis, version 2.0 (Biostat).

### Quality assessment

The Quality In Prognosis Studies tool was used to assess the quality of included studies ([@b31-etm-0-0-7995]). The tool comprises six areas: Participation, attrition, measurement of prognostic factors, measurement of and controlling for confounding variables, measurement of outcomes and analytic approaches. The quality of included studies was independently appraised by two reviewers JHH and NJL. Any discrepancies were resolved by a third reviewer MLC.

Results
=======

### Study selection

A flow chart of the study selection process is presented in [Fig. 1](#f1-etm-0-0-7995){ref-type="fig"}. A total of 431 studies were initially identified, of which 52 were evaluated for selection for the meta-analysis. After excluding 44 studies (5 studies did not report primary outcomes; 34 had different objectives; 1 was a commentary; 2 were duplicates; and 2 did not have full texts available), a total of 8 studies were included in the final analysis ([@b19-etm-0-0-7995],[@b20-etm-0-0-7995],[@b22-etm-0-0-7995],[@b26-etm-0-0-7995],[@b32-etm-0-0-7995]--[@b35-etm-0-0-7995]).

### Study characteristics

The present meta-analysis included 5 prospective studies, 2 retrospective studies and 1 randomized controlled trial (RCT). The analysis included a total of 533 subjects in the SVR group and 346 subjects in the non-SVR group. The age of study subjects ranged from 40.4 to 63.2 years, and the percentage of males ranged from 45.5 to 85.2%. The follow-up time was 6 months after EOT in 7 studies, while one study had a follow-up time of 24 months after EOT ([Table I](#tI-etm-0-0-7995){ref-type="table"}). A comparison of the incidence rate of IR, as well as HOMA-IR scores, HOMA-β scores, fasting glucose levels and fasting insulin levels between the baseline and EOT is provided in [Table II](#tII-etm-0-0-7995){ref-type="table"}.

Meta-analysis
-------------

### Reduction in incidence of IR

Only the two studies which reported complete data for the IR rate (basal value and value after EOT) were considered for the meta-analysis ([@b19-etm-0-0-7995],[@b26-etm-0-0-7995]). A fixed-effect model was applied according to the heterogeneity test \[Q-value=0.002; degrees of freedom (df)=1; P=0.969; I^2^=0%\]. The combined analysis indicated that the SVR and non-SVR groups had a similar reduction in IR rate (odds ratio=0.995; 95%CI=0.613--1.616; P=0.984; [Fig. 2](#f2-etm-0-0-7995){ref-type="fig"}).

### Reduction in mean HOMA-IR

All of the 8 studies reported a change in HOMA-IR between the basal value and the value after EOT, and were therefore considered for meta-analysis. A random-effects model was applied according to the heterogeneity test (Q-value=16.991; df=7; P=0.017; I^2^=58.80%). The combined analysis indicated that the SVR group had a significantly higher mean reduction in HOMA-IR compared with the non-SVR group (difference in means=−0.485; 95%CI=−0.713 to −0.256; P\<0.001). In addition, subgroup analysis indicated similar changes in Asian and non-Asian studies (Asian: Difference in means=−0.475; 95%CI=−0.806 to −0.144; P=0.005; non-Asian: Difference in means=−0.483; 95%CI=−0.782 to −0.183; P=0.002; [Fig. 3](#f3-etm-0-0-7995){ref-type="fig"}). [Table SI](#SD1-etm-0-0-7995){ref-type="supplementary-material"} summarizes the meta-analysis for studies with genotypes 1/2. The results indicated that the SVR group had a higher mean reduction in HOMA-IR as compared with the non-SVR group (difference in means=−0.403; P=0.007). However, the change in HOMA-IR was similar between the SVR and non-SVR groups after removing the study by Kawaguchi *et al* ([@b20-etm-0-0-7995]) from 2007 (difference in means=−0.233, P=0.241; [Table SI](#SD1-etm-0-0-7995){ref-type="supplementary-material"}).

### Reduction in mean HOMA-β

Only three studies reported the complete data for the change in HOMA-β scores between the basal value and the value after EOT and were considered for meta-analysis ([@b20-etm-0-0-7995],[@b32-etm-0-0-7995],[@b35-etm-0-0-7995]). A fixed-effects model was used according to the heterogeneity test (Q-value=0.521; df=2; P=0.771; I^2^=0%). The combined analysis indicated that the SVR group had a significantly higher mean reduction in HOMA-β scores compared with that in the non-SVR group (difference in means=−15.448; 95%CI=−23.326 to −7.570; P\<0.001; [Fig. 4](#f4-etm-0-0-7995){ref-type="fig"}). [Table SI](#SD1-etm-0-0-7995){ref-type="supplementary-material"} summarizes the results of a subgroup analysis for genotypes 1/2. The results suggested that the SVR group had a higher mean reduction in HOMA-β scores than the non-SVR group (difference in means=−15.179; P\<0.001). However, the change in HOMA-β scores was similar between the SVR and non-SVR groups after excluding the study by Kawaguchi *et al* ([@b20-etm-0-0-7995]) (difference in means=−33.0; P=0.445; [Table SI](#SD1-etm-0-0-7995){ref-type="supplementary-material"}).

### Sensitivity analysis

Sensitivity analyses were performed for HOMA-IR reduction using a leave-one-out approach ([Fig. 5](#f5-etm-0-0-7995){ref-type="fig"}). There was no significant difference in the direction and magnitude of the combined estimates with the removal of any one study, indicating that the meta-analysis had good reliability and that the data were not overly influenced by any given study.

### Quality assessment

In general, the quality of the analysis was good, with a low risk of bias in terms of study participation, study attrition, measurement of prognostic factors, measurement of outcomes and analytic approaches ([Fig. 6](#f6-etm-0-0-7995){ref-type="fig"}). The risk of bias regarding confounding was unclear in all included studies.

Discussion
==========

The present meta-analysis evaluated data from 8 studies comparing the reduction in IR between SVR and non-SVR groups of HCV patients treated with IFN-based therapy. The pooled analysis indicated no significant difference in the reduction of IR between the SVR and non-SVR groups. However, patients who achieved SVR had a significantly higher mean reduction in HOMA-IR and HOMA-β scores compared to patients in the non-SVR group.

The HOMA-IR score has been indicated to be a predictor of liver fibrosis and may be used as a surrogate marker for SVR at EOT ([@b33-etm-0-0-7995]). A previous meta-analysis of 13 studies reported that elevated HOMA-IR (regardless of cut-off value, as well as with the cut-off value set at \>2) was associated with lower SVR rates after IFN-based therapy in patients infected with HCV of the genotype 1, 2 or 3 ([@b36-etm-0-0-7995]). Another study indicated that SVR was associated with a reduction in the mean HOMA-IR in patients with genotype 1 of HCV, but not in those with genotypes 2 or 3 ([@b25-etm-0-0-7995]). In addition, HOMA-IR continued to decrease at the end of the follow-up in patients with genotype 4 HCV who achieved SVR, but remained unchanged in non-SVR patients ([@b34-etm-0-0-7995]). In the present study, a subgroup analysis was only performed for genotypes 1/2. The mean reduction of HOMA-IR and HOMA-β scores was higher in patients who achieved SVR. However, the results became insignificant after removing the study by Kawaguchi *et al* ([@b20-etm-0-0-7995]) from 2007. To further confirm and clarify the present results, further studies are required. A more complete understanding of the role of the genotype of HCV in the interaction between IR and SVR is needed, since the genotype impacts SVR rates ([@b37-etm-0-0-7995]).

The baseline HOMA-IR score is considered an important determinant of viral response, since it was demonstrated to be lower in responders than in non-responders ([@b16-etm-0-0-7995],[@b32-etm-0-0-7995]). HCV patients who failed to achieve SVR exhibited an increase in mean post-treatment HOMA-IR scores compared to the baseline value ([@b19-etm-0-0-7995]). In addition, the mean pre-treatment HOMA-IR score was indicated to be similar in the SVR and non-SVR groups, although the HOMA-IR scores significantly improved at the EOT only in the SVR group ([@b33-etm-0-0-7995]). It was recently reported that viral clearance improved insulin sensitivity in CHC patients with baseline IR, while it increased the HOMA-IR in patients without baseline IR ([@b38-etm-0-0-7995]). One explanation may be that baseline IR is due to HCV infection, which is known to impair the host\'s glucose metabolism ([@b39-etm-0-0-7995]).

Of note, although a recent meta-analysis of 17 studies concluded that IR was associated with a 3-fold higher risk of failure to achieve SVR, regardless of viral genotype, certain studies included failed to demonstrate an association between IR and SVR ([@b24-etm-0-0-7995]). This result was attributed to a number of factors, including differences between the studies in calculating and interpreting HOMA-IR scores, inclusion of easy-to-cure cohorts and the presence of other variables strongly associated with IR ([@b24-etm-0-0-7995]). The present meta-analysis indicated no significant difference in the reduction of IR rates between the SVR and non-SVR groups, although the SVR group had a significantly higher mean reduction in HOMA-IR scores compared to the non-SVR group. It is important to note that only 2 studies included in the present meta-analysis provided complete data for IR rates ([@b19-etm-0-0-7995],[@b26-etm-0-0-7995]). In addition, each study used a different HOMA-IR cut-off value. The present results suggest that it may be necessary to evaluate baseline IR in order to elucidate the impact of SVR on IR. It may also be useful to analyze the rates of *de-novo* IR development, since it has been previously reported that non-diabetic CHC patients who achieved SVR after IFN-based therapy had lower rates of *de-novo* IR compared to non-SVR patients ([@b19-etm-0-0-7995]).

The present meta-analysis included three studies reporting on the HOMA-β score in the SVR and non-SVR groups ([@b20-etm-0-0-7995],[@b32-etm-0-0-7995],[@b35-etm-0-0-7995]). These studies all indicated that patients who achieved SVR had a significant reduction in their HOMA-β values compared with the non-SVR group. The results of the pooled analysis (combined effect) were consistent with the individual analysis results of the individual studies. This suggested that HOMA-β, a measure of insulin secretion in the pancreas, had a significantly higher mean reduction after EOT vs. baseline in the SVR group compared with that in the non-SVR group. These results further support that SVR is not merely a surrogate marker of therapeutic efficacy, but an actual aim to pursue in most HCV-infected patients. The present results also suggest that clinical management of IR and serum glucose levels may be an important way to impact the therapeutic response in HCV patients. Furthermore, L-arginine supplementation was reported to improve insulin sensitivity in rats fed a high-fat diet, and might be beneficial in the treatment of HCV patients in the future ([@b40-etm-0-0-7995]).

The present study has several strengths and limitations. Of note, it is the first systematic review and meta-analysis to indicate that HCV patients who achieved SVR after IFN therapy had improved HOMA-IR and HOMA-β scores. Furthermore, the present study followed the PRISMA guidelines, which enables transparent and complete reporting ([@b29-etm-0-0-7995]). Regarding the limitations, only one RCT was included. In addition, the study did not include any subgroup analysis for HCV genotypes 3/4 or different HOMA-IR cut-off scores. Furthermore, other factors correlated with IR, e.g. insulin-like growth factor-1, were not evaluated ([@b41-etm-0-0-7995]). Finally, the number of studies analyzing IR rates and HOMA-β was small.

In conclusion, the present study revealed that HCV patients who achieved SVR after IFN-based therapy exhibited improvement in HOMA-IR and HOMA-β scores. However, since no reduction in IR rates was determined, it is important to interpret the results with caution. Further studies are required to evaluate the complex association between SVR and IR.
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###### 

Summary of study characteristics of the eight studies included in the meta-analysis.

  1st author (year)   Study design    Study period of patients   Number   Compared groups        Treatment protocol (dose, duration)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Age (years)   Males (%)   Genotype (n)       Country     Follow-up time        (Refs.)
  ------------------- --------------- -------------------------- -------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ----------- ------------------ ----------- --------------------- -----------------------
  Jung (2014)         Retrospective   Jan 5 2005 to Dec 2011     49       SVR                    n.s.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             48±11.2       n.s         1/non-1: 28/21     Korea       6 months after EOT    ([@b32-etm-0-0-7995])
                                                                 11       Non-SVR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 56.6±9.9                  1/non-1: 8/3                                         
  Chan (2013)         Prospective     2003--2007                 48       SVR                    All but five patients received PEG-IFN-2a and weight-based RBV therapy (1,000 mg for patients with BW \<75 kg or 1,200 mg daily for patients with a BW \>75 kg). The remaining 5 received PEG-IFN-2b and weight- based RBV therapy. Treatment duration was genotype-dependent (12 months for genotype 1 and 6 months for genotypes 2 and 3)                                                                                                                                                                      42±10         24 (50)     1/2/3: 24/6/17     Australia   6 months after EOT    ([@b33-etm-0-0-7995])
                                                                 38       Non-SVR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               21 (55)     1/2/3: 20/4/13                                       
  Aghemo (2012)       RCT             MIST sub-study             230      SVR                    Combination of PEG-IFN-2a (180 g/week) and RBV (800--1,200 mg/day) or a combination of PEG-IFN-2b (1.5 g/kg/week) and daily RBV (800--1,200 mg) for a standard duration based on the HCV genotype.                                                                                                                                                                                                                                                                                                                                         1/4: 78 2/3: 152   Italy       24 months after EOT   ([@b19-etm-0-0-7995])
                                                                 124      Non-SVR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 n.s.          n.s.        1/4: 94 2/3: 30                                      
  Khattab (2012)      Prospective     Feb 2008 to Jan 2011       61       SVR                    Peg-IFNα-2a (180 g/week) or a combination of Peg-IFNα-2b (1.5 g/kg/week) and RBV (1,000 mg or 1,200 mg/day for BW≤ or \>75 kg, respectively) during the study period for 48 weeks independent of the rapid virological response.                                                                                                                                                                                                                                                                                 40.4±5.8      52 (85.2)   4: 107             Egypt       6 months after EOT    ([@b34-etm-0-0-7995])
                                                                 46       Non-SVR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 42.8±5.1      34 (73.9)                                                        
  Kim (2009)          Prospective     May 2004 to Nov 2006       22       Sustained Responders   Combination of Peg-IFNα-2a (180 µg) and RBV (800--1,000 mg/day, according to the genotype of HCV)                                                                                                                                                                                                                                                                                                                                                                                                                57.6±8.9      10 (45.5)   1b/2a: 9/13        Korea       6 months after EOT    ([@b22-etm-0-0-7995])
                                                                 6        Non-responder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           50.8±9.6      4 (66.7)    1b/2a: 6/0                                           
  Kawaguchi (2009)    Retrospective   Jan 2002 to Aug 2007       48       SVR                    Patients with a high viral load or past history of IFN treatment received 6 or 10 MU of IFN-2b three times a week for 24 weeks plus RBV 600--1,000 mg/day and were treated with Peg-IFN-2b 1.5 mg/kg/week plus RBV daily for 48 weeks (genotype 1) or 24 weeks (genotype 2). Patients with a low viral load received 5-10MU of natural IFN three times a week for 24 weeks or 6 MU of IFN daily for 8 weeks and were treated with Peg-IFNα-2a 180 mg/week for 24--48 weeks or the above-mentioned IFN regimen.   52.3±12.1     35 (72.9)   1/2: 31/17         Japan       6 months after EOT    ([@b35-etm-0-0-7995])
                                                                 24       Non-SVR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 56.1±8.1      13 (54.2)   1/2: 21/3                                            
  Petta (2009)        Prospective     May 2005 to Nov 2006       46       SVR                    n.s.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             47.0±12.6     30 (65.2)   1: 83              Italy       6 months after EOT    ([@b26-etm-0-0-7995])
                                                                 20       Relapsers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               54.7±11.9     17 (45.9)                                                        
                                                                 17       Non-responders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Kawaguchi (2007)    Prospective     n.s.                       29       SVR                    n.s.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             58.5±8.6      19 (65.5)   1/2: 11/18         Japan       6 months after EOT    ([@b20-etm-0-0-7995])
                                                                 48       Non-responders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          61.7±7.7      27 (56.2)   1/2: 42/6                                            
                                                                 12       Relapsers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               63.2±6.1      8 (1.5)     1/2: 10/2                                            

Values are expressed as the mean ± standard deviation or n (%). SVR, sustained viral response; EOT, end of treatment; Peg-IFN, pegylated interferon; RBV, ribavirin; MU, million units; BW, body weight; HCV, hepatitis C virus; n.s., not specified.

###### 

Summary of the clinical outcomes at the first visit and after EOT for all included studies.

  1st author (year)   Compared groups   Basal incidence of IR (%)   Incidence of IR after EOT (%)   Basal HOMA-IR   HOMA-IR after EOT                           Basal HOMA-   HOMA- after EOT   Basal FPG (mg/dl)   FPG after EOT (mg/dl)   Basal fasting insulin (µU/ml)   Fasting insulin after EOT (µU/ml)   (Refs.)
  ------------------- ----------------- --------------------------- ------------------------------- --------------- ------------------------------------------- ------------- ----------------- ------------------- ----------------------- ------------------------------- ----------------------------------- -----------------------
  Jung (2014)         SVR               n.s.                        n.s.                            3.4±2.69        2.5±0.2                                     149.6±117     104.3±6.5         n.s.                n.s.                    n.s.                            n.s.                                ([@b32-etm-0-0-7995])
                      Non-SVR           n.s.                        n.s.                            3.4±2.31        3.1±0.2                                     111.1±65.6    102.2±5.3         n.s.                n.s.                    n.s.                            n.s.                                
  Chan (2013)         SVR               n.s.                        n.s.                            3.0±1.0         2.3±0.7                                     n.s.          n.s.              n.s.                n.s.                    n.s.                            n.s.                                ([@b33-etm-0-0-7995])
                      Non-SVR           n.s.                        n.s.                            3.1±0.7         3.1±0.9                                     n.s.          n.s.              n.s.                n.s.                    n.s.                            n.s.                                
  Aghemo (2012)       SVR               HOMA score \>2: 12%         10%                             1.11±0.8        1.18±1.1                                    n.s.          n.s.              n.s.                n.s.                    n.s.                            n.s.                                ([@b19-etm-0-0-7995])
                      Non-SVR           HOMA score \>2: 11%         19%                             1.20±0.85       1.49±1.3                                    n.s.          n.s.              n.s.                n.s.                    n.s.                            n.s.                                
  Khattab (2012)      SVR               n.s.                        n.s.                            2.03±0.6        1.2±0.3                                     n.s.          n.s.              4.5±0.6 (mmol/l)    n.s.                    13.7±5.1                        n.s.                                ([@b34-etm-0-0-7995])
                      Non-SVR           n.s.                        n.s.                            4.05±0.8        Non-responders: 3.77±0.6 Relapsers: 2±0.4   n.s.          n.s.                                  n.s.                                                    n.s.                                
  Kim (2009)          SVR               HOMA-IR \>3: 14 (63.6)                                      5.28±4.55       2.62±1.07                                   n.s.          n.s.              112.6±33.0          99.9±14.9               18.13±14.24                     10.40±3.12                          ([@b22-etm-0-0-7995])
                      Non-SVR           HOMA-IR \>3: 4 (66.7)                                       3.34±1.24       3.4 5± 1.28                                 n.s.          n.s.              105.5±15.2          107.0±14.6              12.50±3.16                      13.06±4.02                          
  Kawaguchi (2009)    SVR               n.s.                        n.s.                            1.86±1.08       1.67±0.93                                   174±211       105±60            n.s.                n.s.                    n.s.                            n.s.                                ([@b35-etm-0-0-7995])
                      Non-SVR           n.s.                        n.s.                            2.50±1.13       2.50±1.31                                   193±145       157±126           n.s.                n.s.                    n.s.                            n.s.                                
  Petta (2009)        SVR               HOMA ≤2.7: 30%              8.80%                           2.64±1.85       1.53±0.92                                   n.s.          n.s.              n.s.                n.s.                    11.9±7.3                        n.s.                                ([@b26-etm-0-0-7995])
                      Relapsers         HOMA ≤2.7: 30%              19.30%                          2.64±1.16       1.85±0.80                                   n.s.          n.s.              n.s.                n.s.                    12.5±5.8                        n.s.                                
                      Non-responders    HOMA ≤2.7:                  17.50% 52%                      3.10±1.80       2.05±0.84                                   n.s.          n.s.              n.s.                n.s.                                                    n.s.                                
  Kawaguchi (2007)    SVR               n.s.                        n.s.                            3.07±0.95       2.2±0.7                                     113.7±21.3    92.6±14.0         n.s.                n.s.                    n.s.                            n.s.                                ([@b20-etm-0-0-7995])
                      Non-responders    n.s.                        n.s.                            3.95±1.69       3.6±1.2                                     120.0±26.1    112.4±24.1        n.s.                n.s.                    n.s.                            n.s.                                
                      Relapsers         n.s.                        n.s.                            3.73±1.21       3.6±1.2                                     121.5±13.3    117.4±17.4        n.s.                n.s.                    n.s.                            n.s.                                

Values are expressed as the mean ± standard deviation or n (%). SVR, sustained viral response; EOT, end of treatment; HOMA, homeostasis model assessment; IR, insulin resistance; FPG, fasting plasma glucose.
